The Difficult-to-Treat del 17 p Patient-A Case Report in Chronic Lymphocytic Leukemia.
17 p deletion
allogeneic stem cell transplantation
chronic lymphocytic leukemia
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
24 Dec 2021
24 Dec 2021
Historique:
received:
16
11
2021
revised:
21
12
2021
accepted:
22
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
Chronic lymphocytic leukemia (CLL) treatment strategies have evolved to include mechanism-driven drugs but now raise new questions regarding their optimum timing and sequencing. In high-risk patients, switching from pathway inhibitors to allogeneic stem cell transplantation (allo-HCT) is still a matter of intense debate. We report the case of a CLL patient with 17 p deletion treated with ibrutinib as a bridge to allo-HCT. Early relapse after allo-HCT urged the initiation of salvage therapy, including donor lymphocytes infusions, ibrutinib, and venetoclax. We aim to outline and discuss the potential benefits of novel therapies, the current role of allo-HCT in CLL, drug timing and sequencing, and the unmet need to improve the long-term outcome of high-risk CLL patients.
Identifiants
pubmed: 35056341
pii: medicina58010033
doi: 10.3390/medicina58010033
pmc: PMC8778873
pii:
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Références
Haematologica. 2020 Oct 13;106(9):2354-2363
pubmed: 33054121
Blood. 2021 Sep 9;138(10):836-846
pubmed: 34115103
Cancer. 2011 Oct 15;117(20):4679-88
pubmed: 21455998
J Clin Oncol. 2018 Jul 1;36(19):1973-1980
pubmed: 29715056
Lancet Oncol. 2016 Oct;17(10):1409-1418
pubmed: 27637985
Oncotarget. 2016 Dec 6;7(49):80916-80924
pubmed: 27821812
Bone Marrow Transplant. 2017 Mar;52(3):372-380
pubmed: 27941763
J Clin Oncol. 2008 Oct 20;26(30):4912-20
pubmed: 18794548
Am J Hematol. 2019 Dec;94(12):1353-1363
pubmed: 31512258
Leukemia. 2013 Feb;27(2):362-9
pubmed: 22955330
J Clin Oncol. 2019 Feb 1;37(4):269-277
pubmed: 30523712
Blood. 2020 Apr 9;135(15):1204-1213
pubmed: 31876911
Biol Blood Marrow Transplant. 2008 Jan;14(1):50-8
pubmed: 18158961
Blood. 2014 May 22;123(21):3247-54
pubmed: 24652989
Leukemia. 2007 Jan;21(1):12-7
pubmed: 17109028
Clin Cancer Res. 2018 Sep 15;24(18):4371-4379
pubmed: 29895707
Blood. 2017 Nov 23;130(21):2243-2250
pubmed: 28924018
N Engl J Med. 2000 Dec 28;343(26):1910-6
pubmed: 11136261
Blood. 2018 Apr 26;131(17):1910-1919
pubmed: 29437592
Clin Cancer Res. 2017 Feb 1;23(3):735-745
pubmed: 27503198
Blood. 2012 May 3;119(18):4101-7
pubmed: 22394601
Blood. 2019 Mar 14;133(11):1205-1216
pubmed: 30602617
Blood. 2018 Dec 6;132(23):2446-2455
pubmed: 30287523
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Blood. 2016 Jul 21;128(3):395-404
pubmed: 27226433
Blood. 2017 Sep 21;130(12):1477-1480
pubmed: 28716861
Br J Haematol. 2012 Apr;157(1):67-74
pubmed: 22224845
J Clin Oncol. 2017 May 1;35(13):1437-1443
pubmed: 28418267
Blood. 2017 Mar 9;129(10):1270-1274
pubmed: 28096090
Transfus Apher Sci. 2016 Jun;54(3):345-55
pubmed: 27216544
J Clin Oncol. 2020 Dec 1;38(34):4042-4054
pubmed: 32986498
J Clin Oncol. 2019 Jun 1;37(16):1391-1402
pubmed: 30995176
Haematologica. 2010 Oct;95(10):1705-12
pubmed: 20511662
Cancer Discov. 2019 Mar;9(3):342-353
pubmed: 30514704
Blood. 2010 Oct 7;116(14):2438-47
pubmed: 20595516
Bone Marrow Transplant. 2016 Jun;51(6):769-70
pubmed: 27159178
Blood. 2009 Jul 30;114(5):957-64
pubmed: 19414856
Bone Marrow Transplant. 2019 Jan;54(1):44-52
pubmed: 29728701
Clin Cancer Res. 2020 Aug 1;26(15):3918-3927
pubmed: 32209572
Blood. 2015 Apr 16;125(16):2497-506
pubmed: 25700432
Blood. 2013 Oct 10;122(15):2539-49
pubmed: 23886836
Br J Haematol. 2017 Aug;178(4):521-533
pubmed: 28589551